INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,636 | -17.7% | 89 | 0.0% | 0.00% | -33.3% |
| Q2 2023 | $5,635 | +16.9% | 89 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $4,819 | +2.3% | 89 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $4,710 | -32.7% | 89 | -39.9% | 0.00% | -25.0% |
| Q3 2022 | $7,000 | -12.5% | 148 | 0.0% | 0.00% | -20.0% |
| Q2 2022 | $8,000 | 0.0% | 148 | 0.0% | 0.01% | +25.0% |
| Q4 2021 | $8,000 | +33.3% | 148 | 0.0% | 0.00% | +33.3% |
| Q3 2021 | $6,000 | 0.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $6,000 | +20.0% | 148 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $5,000 | -16.7% | 148 | -24.1% | 0.00% | -25.0% |
| Q4 2020 | $6,000 | +20.0% | 195 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $5,000 | +66.7% | 195 | -43.5% | 0.01% | +150.0% |
| Q3 2019 | $3,000 | -40.0% | 345 | -9.2% | 0.00% | -33.3% |
| Q2 2019 | $5,000 | 0.0% | 380 | 0.0% | 0.00% | -25.0% |
| Q1 2019 | $5,000 | -44.4% | 380 | -3.8% | 0.00% | 0.0% |
| Q3 2018 | $9,000 | – | 395 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |